(from left) Winselow Tucker, President and GM, Eli Lilly India; Stefan Miltenyi, Founder & President, Miltenyi Biotec, Germany; GV prasad, Co-Chairman & MD, Dr Reddy’s Laboratories; Eric Mansion, GM, India & South-East Asia, Sanofi, Singapore, and Shreehas Tambe, MD & CEO, Biocon Biologics, through the ‘CEO Conclave – Future of Pharma & Biotech (’26-’30): Growth, Headwinds & Alternatives’, at BioAsia 2026, Hyderabad, on Tuesday
| Picture Credit score:
NAGARA GOPAL
To additional harness international alternative in pharma and life sciences, Indian trade wants to maneuver up on the value chain to change into a functionality chief with focus on high-value merchandise, in accordance with trade captains.
The journey in direction of this finish has simply begun and will take a decade or extra to attain tangible outcomes, stated panelists of a dialogue on the long run of pharma and biotech over the following 5 years, through the CEO Conclave on the BioAsia 2026, right here on Tuesday.
“India did change into the generic pharma hub of the world, whereas value lies in innovation and quantity lies in generics. There could not be any vital shift in product portfolio in the following 5 years, however growth can now be seen in biologicals and providers,’’ stated GV Prasad, Co-Chairman, Dr Reddy’s Laboratories.
Nonetheless, an ecosystem for impactful R&D in value based mostly merchandise is underway with many international majors organising international functionality centres (GCCs) in India, which might increase innovation, Prasad stated.
Echoing Prasad, Shreehas Tambe, MD & CEO, Biocon Biologics, stated that Indian generics trade did make the nation proud. “We have now carried out effectively in price arbitrage and reverse innovation, with high quantity of exports and low value. It’s time to maneuver up on the value chain by innovation,’’ he stated.
India must construct functionality management together with capability management, which it already enjoys. 5 years from now would be “too quickly” to witness massive shifts in the trade, he stated, including, “However we might see new beginnings.’’
Key necessities for the following part of growth are: Differential pricing, innovation, a technology-enabled ecosystem with sturdy software of Augmented Intelligence would be important going ahead, in accordance o Winselow Tucker, President and GM, Eli Lilly and Firm (India).
From a regulatory level of view, a unique coverage shift was additionally wanted with provisions to reward breakthrough innovation, he stated.
Capex
Is investing in innovation and drug discovery an enormous problem for Indian firms? For GV Prasad, whereas greater expenditure on R&D in new molecules is all the time “lovable”, there may be additionally a necessity to point out return on funding to the traders as it might minimize down margins and revenue earlier than tax. “We will nonetheless spend extra on R&D, nevertheless it will not be enough,’’ Prasad stated. Nonetheless, there have been methods to fund greater R&D by collaborations and different fashions, he added.
“There is no such thing as a valuation to the product pipeline in India and traders, together with enterprise capitalists, would need to see revenue visibility,’’ Prasad stated.
Although there are dangers, Biocon had an innovation-led tradition, in accordance with Tambe. “We took bets which aren’t typical,’’ he stated, including the end result of R&D investments would resolve the investor notion.
Printed on February 17, 2026
Source link
#growth #pharma #life #sciences #high #merchandise #CEOs
